Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
12/21/2010
Trade Name:
INOmax
Generic or Proper Name (*):
nitric oxide
Indications Studied:
Prevention of bronchopulmonary dysplasia
Therapeutic Category:
Pulmonary vasodilator
Ages Studied:
7-21 days
Study #:
2
Study Type:
Efficacy/Safety
Study Design:
Single-Blind/Placebo
No Patients:
584
No Centers:
21
No Countries:
1
BPCA(B), PREA(P):
B
Asian:
0
Black:
164
Other:
99
White:
303
Unknown:
18
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
0
Hispanic/Latino:
0
Non-Hispanic/Non Latino:
0
Countries:
US
-
-